RxDoctor Payments Data

Eileen McGrath, MD

Family Medicine · Santa Monica, CANPI 1558398339

Payments from drug & device makers

$1,880in general payments, 2019–2025

Across 53 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$863
  • Novo Nordisk$359
  • Lilly USA, LLC$181
  • Gilead$138
  • Merck$115
  • GSK$49
  • plus $175 from 7 others

What the payments were for

  • Food & beverage$1,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,880 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$130,290
Medicare patients
310
Services billed
2,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$49,351
MounjaroTirzepatide20$29,184
XareltoRivaroxaban11$15,337
OzempicSemaglutide13$12,215
PremarinEstrogens, Conjugated33$11,401
Combivent RespimatIpratropium/Albuterol Sulfate14$9,563
EstringEstradiol12$5,946
Breo ElliptaFluticasone/Vilanterol11$4,582
Estradiol80$4,469
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol11$3,815
Rosuvastatin Calcium150$3,433
Atorvastatin Calcium258$3,371
SynthroidLevothyroxine Sodium40$3,287
Levothyroxine Sodium171$3,182
Losartan Potassium193$2,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Estring$35$66,69779 claims
Lilly USA, LLCMounjaro$181$29,18420 claims
Novo NordiskOzempic$359$12,21513 claims
GSKBreo Ellipta$49$4,58211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →